Related Experiment Video
Updated: Jul 19, 2026

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
Acetylsalicylic acid as an adjuvant therapy for schizophrenia
Wijnand Laan1, Jean-Paul Selten, René S Kahn
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. W.Laan@umcutrecht.nl
Background:
Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.
Methods:
To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters. This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drug Therapy
Antianxiety Medications
Alzheimer's Disease: Treatment
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Psychological and Sociocultural Causes of Schizophrenia